Searchable abstracts of presentations at key conferences in endocrinology

ea0063p565 | Diabetes, Obesity and Metabolism 2 | ECE2019

Giant prolactinoma associated with alopecia universalis (AU): a case report

Liesionyte Kristina , Pauliukiene Renata , Knispelis Robertas

Introduction: Giant prolactinomas are rare tumours, they represent range from 0.5 to 4.0% of all pituitary tumours. We are presenting a patient with giant prolactinoma without visual field defects and any obvious clinical symptoms related to hyperprolactinemia and probably associated with alopecia universalis.Case: 32 years old man has visited outpatient department of our hospital, complaining of severe headache for the last three years. He underwent bra...

ea0063ep114 | Pituitary and Neuroendocrinology | ECE2019

sLiving with acromegaly: depicting acromegaly treatment evolution in 18 years period

Juskiene Martyna , Knispelis Robertas , Zilaitiene Birute

Introduction: Pituitary adenomas are benign intracranial tumors. However, some of them are resistant to multiple medical treatments and are clinically considered to be aggressive.Case report: Twenty years old male patient presented with symptomatic hyperglycemia and general weakness. With suspected diagnosis of type 1 diabetes patient was hospitalized in Kauno Klinikos, Endocrinology Department. In further clinical observation acromegalic appearance noti...

ea0041ep269 | Clinical case reports - Pituitary/Adrenal | ECE2016

Pregnancy in patient with GH secreting pituitary adenoma: a case report

Knispelis Robertas , Lebedevaite Kristina , Lasiene Jurate , Zilaitiene Birute , Verkauskiene Rasa

Introduction: GH producing pituitary adenomas are associated with infertility. Hereby the first case in Lithuania, when acromegaly patient got pregnant and delivered is reported.Case presentation: 33-year-old woman visited endocrinologist complaining of secondary amenorrhoea. Due to elevated prolactin – 3016 mU/l (NR<418), bromcriptine treatment was started. The patient discontinued treatment after three months because of restoration of regular ...

ea0037ep1100 | Endocrine tumours | ECE2015

Emotional state in men and women with acromegaly after pituitary adenomas

Lasaite Lina , Knispelis Robertas , Lasiene Jurate , Barsiene Lina

Adult patients with acromegaly after pituitary adenomas usually have emotional problems, impaired quality of life. Objective was to detect possible differences of emotional state between patients with acromegaly after pituitary adenomas and healthy age- and sex-matched controls and to outline possible gender-specific differences.Patients and methods: 12 males (age 49.6±10.2 years) and 29 females (age 51.5±9.5 years) with acromegaly after pituit...

ea0056p866 | Pituitary - Clinical | ECE2018

Relationship between pituitary adenoma size and transsphenoidal pituitary adenoma surgery outcomes: single-centre experience

Ramanciuckaite Martyna , Knispelis Robertas , Zalinkevicius Rimantas , Zilaitiene Birute , Verkauskiene Rasa

Introduction: Stereotactic radiotherapy and more relevant pharmacotherapy are widely used for PA’s treatment; however transsphenoidal surgery remains gold standard. Postoperative complications and endocrinological outcomes vary widely and are related with surgeon experience and tumor characteristics.The aim of this study: To determine relationship between pituitary adenoma size and transsphenoidal pituitary adenoma surgery outcomes.<p class="abs...

ea0049ep839 | Clinical case reports - Pituitary/Adrenal | ECE2017

Pituitary apoplexy while treating recurrence of Cushing’s disease with Pasireotide

Zilaitiene Birute , Kondrotiene Aiste , Verkauskiene Rasa , Barsiene Lina , Knispelis Robertas , Sarauskas Valdas , Colao Annamaria

Introduction: ACTH producing macroadenoma and pituitary apoplexy are rare in Cushing’s disease. Somatostatin receptor agonist Pasireotide is indicated for the treatment of patients with Cushing’s disease for whom surgery is not an option or has failed. We present a case of pituitary apoplexy in patient with recurrence of Cushing’s disease treated with Pasireotide.Case: 38 years old female presented with quick weight gain, weakness, irregul...

ea0037gp.07.06 | Reproduction: Female and other | ECE2015

Difficulties in the evaluation of hirsutism using the modified Ferriman-Gallwey scale

Ciaplinskiene Lina , Kozloviene Dalia , Knispelis Robertas , Kriksciuniene Ruta , Zalinkevicius Rimas , Zilaitiene Birute

Inconsistences in hirsutism evaluation using The Modified Ferriman-Gallwey scale (mFG) between different evaluators and need for hirsutism diagnostics standardization has been reported in numerous publications.The aim of the study was to determine the differences in the evaluation of female hirsutism between researchers.Results: The study included healthy 20–34 year old (mean age 25.2 years, 95% CI 23.8–26.5) women with r...

ea0037ep803 | Pituitary: clinical | ECE2015

Transsphenoidal surgery of pituitary adenomas in 491 clinical cases: the retrospective single-centre study

Knispelis Robertas , Zilaitiene Birute , Ramanciuckaite Martyna , Verkauskiene Rasa , Sinkunas Kestutis , Zalinkevicius Rimantas , Tamasauskas Arimantas

Introduction: The number of studies on the incidence and outcomes of surgical treatment for pituitary adenomas is still limited, despite that pituitary tumours are one of the most frequent intracranial tumours.The aim of this study: To evaluate clinical features of transsphenoidaly operated pituitary adenomas (PA) and perioperative results of the treatment.Materials and methods: This is a retrospective single institution study of 4...

ea0073aep518 | Pituitary and Neuroendocrinology | ECE2021

Spontaneous remission in Cushing’s disease: A case report

Radvilė Dobrovolskytė , Birutė Žilaitienė , Knispelis Robertas , Renata Pauliukienė

Spontaneous remission of Cushing disease might be a phase of cyclic disease, but could also be explained by an ACTH-microadenoma infarction or hemorrhage. True remission must be differentiated from cyclic Cushing’s disease with prolonged follow up. 63-years-old female patient was referred to endocrinologist’s and presented with uncontrolled hypertension, type 2 diabetes, central obesity, hirsutism, swelling of the face and legs and a ’buffalo hump’. After a...

ea0073pep8.1 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Oral octreotide capsules lowered incidence and improved severity of acromegaly symptoms compared to injectable somatostatin receptor ligands—results from the MPOWERED trial

Biermasz Nienke , Fleseriu Maria , Dreval Alexander V , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Molitch Mark E , Macut Djuro P , Leonova Nina , Raverot Gerald , Yossi Gilgun-Sherki , Ludlam William H , Patou Gary , Haviv Asi , Gordon Murray B , Urbanavicius Vaidotas , Knispelis Robertas , Melmed Shlomo K , Strasburger Christian J

BackgroundPatients with acromegaly may have high symptom burden. The phase 3 MPOWERED trial assessed control of acromegaly by oral octreotide capsules (OOC; MYCAPSSA®) in comparison to injectable somatostatin receptor ligands (iSRLs) in patients responding to both OOC and iSRLs. iSRLs have been first-line medical treatment for patients with acromegaly for decades. OOC are newly approved in the US for patients previously controlled on iSRL...